Abstract
Endothelial cells have a crucial role in nervous system function and mounting evidence points to endothelial impairment as a major contributor to a wide range of neurological diseases; however, tools to genetically interrogate these cells in vivo remain limited. Here, we describe AAV-BI30, a capsid that specifically and efficiently transduces endothelial cells throughout the central nervous system. At relatively low systemic doses, this vector transduces the majority of arterial, capillary and venous endothelial cells in the brain, retina and spinal cord vasculature of adult C57BL/6 mice. Furthermore, we show that AAV-BI30 robustly transduces endothelial cells in multiple mouse strains and rats in vivo and human brain microvascular endothelial cells in vitro. Finally, we demonstrate the capacity of AAV-BI30 to achieve efficient and endothelial-specific Cre-mediated gene manipulation in the central nervous system. This combination of attributes makes AAV-BI30 well suited to address outstanding research questions in neurovascular biology and aid the development of therapeutics to remediate endothelial dysfunction in disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Statistical data used to generate the graphs presented throughout the manuscript are provided in the form of source data and supplementary statistical data files. The kiCAP-AAV-BI30, NLS-GFP-miR122-WPRE-pA and pAAV-CAG-Cre-miR122-WPRE-pA plasmids generated in this study have been deposited in the Addgene repository under identification numbers 183749, 183775 and 183776, respectively.
References
Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209 (2016).
Körbelin, J. et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol. Med. 8, 609–625 (2016).
Tervo, D. G. R. et al. A designer AAV variant permits efficient retrograde access to projection neurons. Neuron 92, 372–382 (2016).
Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172–1179 (2017).
Hanlon, K. S. et al. Selection of an efficient AAV vector for robust CNS transgene expression. Mol. Ther. Methods Clin. Dev. 15, 320–332 (2019).
Kumar, S. R. et al. Multiplexed Cre-dependent selection yields systemic AAVs for Targeting distinct brain cell types. Nat. Methods 17, 541–550 (2020).
Nonnenmacher, M. et al. Rapid evolution of blood–brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol. Ther. Methods Clin. Dev. 20, 366–378 (2020).
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W. & Zlokovic, B. V. The role of brain vasculature in neurodegenerative disorders. Nat. Neurosci. 21, 1318–1331 (2018).
Mastorakos, P. & McGavern, D. The anatomy and immunology of vasculature in the central nervous system. Sci. Immunol. 4, eaav0492 (2019).
Vanlandewijck, M. et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475–480 (2018).
Chen, B. R., Kozberg, M. G., Bouchard, M. B., Shaik, M. A. & Hillman, E. M. A critical role for the vascular endothelium in functional neurovascular coupling in the brain. J. Am. Heart Assoc. 3, e000787 (2014).
Longden, T. A. et al. Capillary K+-sensing initiates retrograde hyperpolarization to increase local cerebral blood flow. Nat. Neurosci. 20, 717–726 (2017).
Chow, B. W. et al. Caveolae in CNS Arterioles mediate neurovascular coupling. Nature 579, 106–110 (2020).
Ben-Zvi, A. et al. Mfsd2a is critical for the formation and function of the blood–brain barrier. Nature 509, 507–511 (2014).
Andreone, B. J. et al. Blood–brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron 94, 581–594 (2017).
Chow, B. W. & Gu, C. Gradual suppression of transcytosis governs functional blood–retinal barrier formation. Neuron 93, 1325–1333 (2017).
Kerfoot, S. M. & Kubes, P. Overlapping roles of P-selectin and α4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. 169, 1000–1006 (2002).
Piccio, L. et al. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J. Immunol. 168, 1940–1949 (2002).
Tan, C. et al. Endothelium-derived semaphorin 3g regulates hippocampal synaptic structure and plasticity via neuropilin-2/plexinA4. Neuron 101, 920–937 (2019).
Santisteban, M. M. et al. Endothelium-macrophage crosstalk mediates blood–brain barrier dysfunction in hypertension. Hypertension 76, 795–807 (2020).
Liu, X. X. et al. Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis. J. Exp. Med. https://doi.org/10.1084/jem.20180992 (2020).
Dogbevia, G., Grasshoff, H., Othman, A., Penno, A. & Schwaninger, M. Brain endothelial-specific gene therapy improves experimental Sandhoff disease. J. Cereb. Blood Flow Metab. 40, 1338–1350 (2020).
Chen, D. Y. et al. Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating β-catenin-dependent vascular remodeling. J. Clin. Invest. 131, e135296 (2021).
Nikolakopoulou, A. M. et al. Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. J. Exp. Med. 218, e20202207 (2021).
Cui, Y. et al. Brain endothelial PTEN/AKT/NEDD4-2/MFSD2A axis regulates blood–brain barrier permeability. Cell Rep. 36, 109327 (2021).
Song, X. et al. Genome editing with AAV-BR1-CRISPR in postnatal mouse brain endothelial cells. Int. J. Biol. Sci. 18, 652–660 (2022).
Tabebordbar, M. et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919–4938 (2021).
Huang, Q. et al. Delivering genes across the blood–brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS ONE 14, e0225206 (2019).
Hordeaux, J. et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood–brain barrier. Mol. Ther. 27, 912–921 (2019).
Lagos-Quintana, M. et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12, 735–739 (2002).
Suzuki, T. et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol. Ther. 16, 1719–1726 (2008).
Xie, J. et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 19, 526–535 (2011).
Geisler, A. et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 18, 199–209 (2011).
Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol. Ther. 26, 664–668 (2018).
Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182–188 (2018).
dela Paz, N. G. & D’Amore, P. A. Arterial versus venous endothelial cells. Cell Tissue Res. 335, 5–16 (2008).
Shah, A. V., Birdsey, G. M. & Randi, A. M. Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG. Vasc. Pharmacol. 86, 3–13 (2016).
Graßhoff, H. et al. Short regulatory DNA sequences to target brain endothelial cells for gene therapy. J. Cereb. Blood Flow Metab. https://doi.org/10.1177/0271678X211039617 (2021).
Hill, R. A. et al. Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. Neuron 87, 95–110 (2015).
Bartanusz, V., Jezova, D., Alajajian, B. & Digicaylioglu, M. The blood–spinal cord barrier: morphology and clinical implications. Ann. Neurol. 70, 194–206 (2011).
Stahl, A. et al. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 51, 2813–2826 (2010).
Newman, E. A. Functional hyperemia and mechanisms of neurovascular coupling in the retinal vasculature. J. Cereb. Blood Flow Metab. 33, 1685–1695 (2013).
Hobson, B. & Denekamp, J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 49, 405–413 (1984).
Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140 (2010).
Razani, B. et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121–38138 (2001).
Asterholm, I. W., Mundy, D. I., Weng, J., Anderson, R. G. W. & Scherer, P. E. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metab. 15, 171–185 (2012).
Nitta, T. et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161, 653–660 (2003).
Stenman, J. M. et al. Canonical Wnt signaling regulates organ-specific assembly and dizfferentiation of CNS vasculature. Science 322, 1247–1250 (2008).
Liebner, S. et al. Wnt/β-catenin signaling controls development of the blood–brain barrier. J. Cell Biol. 183, 409–417 (2008).
Daneman, R. et al. Wnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc. Natl Acad. Sci. USA 106, 641–646 (2009).
Tran, K. A. et al. Endothelial β-catenin signaling is required for maintaining adult blood–brain barrier integrity and central nervous system homeostasis. Circulation 133, 177–186 (2016).
Kalucka, J. et al. Single-cell transcriptome atlas of murine endothelial cells. Cell 180, 764–779 (2020).
Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483–486 (2010).
Kisanuki, Y. Y. et al. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230, 230–242 (2001).
Pu, W. et al. Mfsd2a+ hepatocytes repopulate the liver during injury and regeneration. Nat. Commun. 7, 13369 (2016).
Ridder, D. A. et al. TAK1 in brain endothelial cells mediates fever and lethargy. J. Exp. Med. 208, 2615–2623 (2011).
Sawada, Y. et al. High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo. Cerebellum 9, 291–302 (2010).
Khabou, H., Cordeau, C., Pacot, L., Fisson, S. & Dalkara, D. Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity. Hum. Gene Ther. 29, 1235–1241 (2018).
Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. https://doi.org/10.1038/s41593-021-00969-4 (2021).
Ehling, M., Adams, S., Benedito, R. & Adams, R. H. Notch controls retinal blood vessel maturation and quiescence. Development 140, 3051–3061 (2013).
Batista, A. R. et al. Ly6a differential expression in blood–brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B. Hum. Gene Ther. 31, 90–102 (2020).
Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411 (2016).
Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97–110 (2020).
Challis, R. C. et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 14, 379–414 (2019).
McQuin, C. et al. CellProfiler 3.0: next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).
Goldey, G. J. et al. Removable cranial windows for long-term imaging in awake mice. Nat. Protoc. 9, 2515–2538 (2014).
DiMattia, M. A. et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947–6958 (2012).
Acknowledgements
We thank members of the Gu and Deverman laboratories for their insightful feedback throughout the study and their comments on the manuscript during drafting. This research was supported by a National Science Foundation Graduate Research Fellowship (grant no. DGE1745303) (T.K.), an HMS Mahoney Postdoctoral Fellowship (L.K.), an award from the National Institutes of Health (NIH) Common Fund and the National Institute of Neurological Disorders and Stroke through the Somatic Cell Genome Engineering Consortium (UG3NS111689) (B.D.), a Brain Initiative award funded through the National Institute of Mental Health (UG3MH120096) (B.D.), the Stanley Center for Psychiatric Research (B.D.), a Fidelity Biosciences Research Initiative (C.G.), an Allen Distinguished Investigator Award (C.G.), an AHA-Allen Initiative in Brain Health and Cognitive Impairment Award (C.G.), NIH R35NS116820 (C.G), NIH RF1DA048786 (C.G.) and NIH R01 HL153261 (C.G.). The research of C.G. was supported in part by a Faculty Scholar grant from the Howard Hughes Medical Institute. C.G. is an investigator of the Howard Hughes Medical Institute. Imaging was in part performed in the Neurobiology Imaging Facility at Harvard Medical School. This facility is supported in part by the HMS/BCH Center for Neuroscience Research as part of an NINDS P30 Core Center grant (NS072030).
Author information
Authors and Affiliations
Contributions
T.K., K.C., C.G. and B.D. conceived the study and interpreted the results. T.K., K.C., L.K., Q.H., J.W., Q.Z., T.B., I.T., S.P., Y.C. and D.R. performed experiments. V.K. and A.C. assisted with data processing. T.K., K.C., L.K., J.W., Y.C. and B.D. prepared the figures. T.K. wrote the manuscript with input from K.C., B.D. and C.G. and editing from L.K. and Y.C. C.G. and B.D. supervised the project. All authors discussed the experiments and read and approved the manuscript.
Corresponding authors
Ethics declarations
Competing interests
K.C., Q.H. and B.D. are inventors on a provisional patent application filed by the Broad Institute (applicant). The specific aspects of the manuscript covered include modified AAV vectors and methods of making and using the same. B.D. is a scientific founder and scientific advisor of Apertura Gene Therapy. B.D. receives research funding from Apertura Gene Therapy, which was used to generate some of the data in this manuscript. B.D. is on the scientific advisory board of Tevard Biosciences. The remaining authors declare no competing interests.
Peer review
Peer review information
Nature Cardiovascular Research thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Integrated supplementary information
Extended Data Fig. 1 AAV-BI30 is more efficient at transducing hCMEC/D3 cells than AAV9 across a wide range of doses.
hCMEC/D3 cells were grown to confluence in a 24-well plate format. AAV9 or AAV-BI30 carrying a CAG−NLS-GFP-miR122-WPRE genome was applied to cells at 0, 500, 1,000, 5,000, 10,000, or 50,000 vg/cell. 4 days post-treatment the cells were analyzed for GFP expression via flow cytometry. The profiles show data from a single sample from each condition but are representative of n = 2 replicates.
Extended Data Fig. 2 Comparison of the tropism of AAV-BI30 and AAV9.
AAV-BI30 or AAV9 vectors carrying a CAG-NLS-GFP-WPRE genome were intravenously administered to adult C57BL/6 mice at 1 × 1011 vg/animal and transduction was assessed after 7 days. Panels show endogenous NLS-GFP transgene expression in organs throughout the body. Scale bar shown is 200 μm. Images are representative of n = 3 animals per group.
Extended Data Fig. 3 Characterization of the peripheral tropism of AAV-BI30.
AAV-BI30:CAG-NLS-GFP-miR122-WPRE was intravenously administered to adult C57BL/6 mice at 1 × 1011 vg/animal and transduction was assessed after three weeks. Representative images of AAV-BI30 transduction throughout the periphery; high-zoom colocalization of GFP with endothelial markers is shown in the rightmost column. With the notable exception of lung, AAV-BI30 rarely transduced endothelial cells in the microvasculature of peripheral organs – a striking contrast to efficient transduction seen throughout the CNS vasculature. Note residual NLS-GFP expression in hepatocytes of the liver persisting in the presence of miR122 repeats in the viral genome, illustrating AAV-BI30’s potent transduction of this cell type. Transduction observed in kidney glomeruli was non-endothelial; GFP+ cells are most likely mesangial cells. Relatively strong endothelial transduction in the interlobular vessels of the renal medulla and the aorta suggest that AAV-BI30 may achieve transduction of large-diameter arteries and veins throughout the systemic circulation. Scale bars are as follows: 100 μm in fourth column from left, 15 μm in rightmost column, and 25 μm in aorta panel. Images are representative of n = 3 animals.
Extended Data Fig. 4 AAV-BI30 transduces endothelial cells throughout the BALB/cJ and rat brain.
AAV-BI30:CAG-NLS-GFP-miR122-WPRE was intravenously administered at 1 × 1011 vg/animal (BALB/cJ; top) or 1.42 × 1013 vg/kg (rat; bottom). Transduction was assessed after three (BALB/cJ) or four (rat) weeks. Images demonstrate endothelial expression of NLS-GFP transgene throughout brains of each species. Scale bars shown are 200 μm (BALB/cJ third row from left) or 100 μm (BALB/cJ rightmost row & rat). Images are representative of n = 3 BALB/cJ mice, n = 1 rat.
Extended Data Fig. 5 Endothelial transduction by AAV-BI30 is consistent across brain regions.
AAV-BI30:CAG-NLS-GFP-miR122-WPRE was intravenously administered to adult C57BL/6 mice at 1 × 1011 vg/animal and transduction was assessed after three weeks. Images demonstrate high endothelial expression of NLS-GFP transgene throughout the brain. Region-specific endothelial transduction efficiency was as follows: 86 ± 6% in cortex, 81 ± 5% in hippocampus, 85 ± 3% in thalamus, 83 ± 2% in cerebellum (mean ± s.e.m.; n = 3 animals). Compare to 84 ± 4% efficiency measured across entire brain. Scale bars are as follows: third row from left 100 μm; rightmost row 50 μm.
Extended Data Fig. 6 The transduction profile of AAV-BI30 within the brain is highly endothelial-specific.
AAV-BI30 or AAV-BR1 vectors carrying a CAG-NLS-GFP-miR122-WPRE genome were intravenously administered to adult C57BL/6 mice at 1 × 1011 vg/animal and transduction was assessed after three weeks. Left: Representative images of rare instances of neuronal and astrocytic transduction observed following AAV-BI30 administration at the 1 × 1011 vg/animal dose; cell types of interest are demarcated with red arrowheads. Scale bar shown is 50 μm. Right: Quantification of AAV transduction in non-endothelial (GFP+ ERG-) cells per mm2 of cortex using 18 μm sagittal sections of brain. An average of 0.6 ± 0.3 and 10.8 ± 3.0 cells / mm2 (mean ± s.e.m.; n = 3 animals per group) were identified in AAV-BI30 and AAV-BR1 administered cohorts, respectively. Consistent with previous reports, neurons constituted the majority of non-endothelial cells transduced by AAV-BR1. The data presented were compared using an unpaired, two-tailed t-test (t4 = 3.37; P = 0.0281).
Extended Data Fig. 7 AAV-BI30 efficiently transduces the brain’s largest arteries.
AAV-BI30:CAG-NLS-GFP-miR122-WPRE was intravenously administered to an adult C57BL/6 mouse at 5 × 1011 vg/animal and transduction was assessed after 3 weeks. Robust, endothelial-specific transduction was observed throughout the cerebral arteries, Circle of Willis, and the head of the basilar artery. Scale bar shown is 100 μm. Images are representative of n = 1 mouse.
Extended Data Fig. 8 AAV-BI30-mediated gene transfer enables long-term transgene expression in CNS endothelial cells.
AAV-BI30:CAG-NLS-GFP-miR122-WPRE was intravenously administered to adult C57BL/6 mice at 1 × 1011 vg/animal and transduction was assessed after approximately 5 months (152 days). Vascular counterstains displayed are as follows: ICAM2 in brain parenchyma and spinal cord; isolectin in retina; and ERG in pia vasculature. High-zoom colocalization with GFP shown in rightmost column. Scale bars are as follows: middle row 200 μm; rightmost row 50 μm. Images are representative of n = 3 mice.
Extended Data Fig. 9 AAV-BI30-mediated Cre delivery achieves efficient endothelial-specific gene deletion.
A 1 × 1011 vg/animal dose of AAV-BI30:CAG-Cre-miR122-WPRE or saline was intravenously administered to adult Cav1fl/fl mice, and Caveolin-1 protein levels were assessed after four weeks. Representative images of the brain microvasculature show strongly reduced endothelial Caveolin-1 protein levels in AAV-BI30 injected animals. Note lack of Caveolin-1 loss in the smooth muscle cell layer of arterioles, demarcated with red arrowheads. High-zoom colocalization of Caveolin-1 and ICAM2 shown in rightmost column. Scale bars are as follows: second column from right 100 μm; rightmost column 50 μm. Images are representative of n = 3 mice per group.
Extended Data Fig. 10 Comparison of engineered AAV capsids with enhanced CNS endothelial cell transduction.
The heptameric peptides used to generate the listed capsids were uniformly inserted within the surface exposed hypervariable region VIII of the AAV sequence67. Specifically, heptamers are inserted between amino acids 587 & 588 in AAV-PPS and 588 & 589 in AAVs BI30, BR1, PHP.B, PHP.V1, and PHP.V2. AAV-PHP.eB shares AAV-PHP.B’s TLAVPFK insert and additionally contains an AQ to DG mutation at amino acids 587-588 (bracketed sequence).
Supplementary information
Supplementary Information
Supplementary Figs. 1–6
Supplementary Data 1
Statistical data for figures in Supplementary Information
Source data
Source Data Fig. 1
Statistical Source Data.
Source Data Fig. 2
Statistical Source Data.
Source Data Fig. 3
Statistical Source Data.
Source Data Fig. 4
Statistical Source Data.
Source Data Extended Data Fig. 5
Statistical Source Data.
Source Data Extended Data Fig. 6
Statistical Source Data.
Rights and permissions
About this article
Cite this article
Krolak, T., Chan, K.Y., Kaplan, L. et al. A high-efficiency AAV for endothelial cell transduction throughout the central nervous system. Nat Cardiovasc Res 1, 389–400 (2022). https://doi.org/10.1038/s44161-022-00046-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-022-00046-4
This article is cited by
-
Human cell surface-AAV interactomes identify LRP6 as blood-brain barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder
Nature Communications (2024)
-
Systematic multi-trait AAV capsid engineering for efficient gene delivery
Nature Communications (2024)
-
Brain endothelial GSDMD activation mediates inflammatory BBB breakdown
Nature (2024)
-
Gene therapy for CNS disorders: modalities, delivery and translational challenges
Nature Reviews Neuroscience (2024)
-
Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates
Nature Communications (2023)